| Submission declined on 2 May 2023 by
DoubleGrazing (
talk). This submission is not adequately supported by
reliable sources. Reliable sources are required so that information can be
verified. If you need help with referencing, please see
Referencing for beginners and
Citing sources. The content of this submission includes material that does not meet Wikipedia's
minimum standard for inline citations. Please
cite your sources using
footnotes. For instructions on how to do this, please see
Referencing for beginners. Thank you.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: Insufficiently referenced. Please note that per
WP:BLP, in articles on living people every material statement, anything potentially contentious, and all private personal and family details must be clearly supported by inline citations to reliable published sources.
DoubleGrazing (
talk) 08:56, 2 May 2023 (UTC)
Mark Hutchinson | |
|---|---|
|
File:Mark Hutchinson - Australian Research Council Centre of Excellence for Nanoscale BioPhotonics - University of Adelaide Mark Hutchinson in 2020 | |
| Born | Mark Rowland Hutchinson 1978 (age 45–46) |
| Nationality | Australian |
| Alma mater | University of Adelaide (PhD) |
| Scientific career | |
| Fields | |
| Institutions | |
| Thesis | Opioids and immune function: The role of non-classical opioid receptors and the association with pain perception (2004) |
| Website | https://researchers.adelaide.edu.au/profile/mark.hutchinson |
Mark Rowland Hutchinson (born 1978) is an Australian scientist and academic who is recognized for his significant contributions to the field of neuroimmunology, particularly in the areas of pain, stress, and drug dependence. He is currently a Professor in the School of Biomedicine at the University of Adelaide and Director of the ARC Centre of Excellence for Nanoscale BioPhotonics. He leads the Neuroimmunopharmacology laboratory and is the Lead of the Human Integrated Sensory System Program for the Defence Science Technology Group. He is currently the President. [1] of Science and Technology Australia, member of the Australian Research Council CEO Advisory committee [2], founding member of the Defence Science Technology Group Advisory Council responsible for overseeing the CBRN STaR Shot, co-chair of the SABRE (Safeguarding Australia through Biotechnology Response and Engagement) Alliance [3], founding executive member of The Animal Welfare Collaborative (TAWC), chair of the Australian Pain Solutions Alliance steering committee, and chair of the Davies Livestock Research Centre Advisory Board.
Education
Hutchinson received a Bachelor of Science degree with majors in Immunology, Microbiology, and Pharmacology from the University of Adelaide. This was followed by a first class Honours in Pharmacology. He then pursued a Doctor of Philosophy degree in Medicine with a focus on Pharmacology from the same university in 2004. His is passionate about life long learning and has recently received training in not-for-profits board of directors from the Australian Institute for Company Directors.
Career and research
Hutchinson's research career began in 2004 as a postdoctoral researcher at the University of Colorado Boulder with Distinguished Professors Linda Watkins and Steven Maier. Here we was supported by an American Australian Association Merck Company Foundation Fellowship [4] and an NHMRC CJ Martin Fellowship [5]. In 2009 he returned to the University of Adelaide in the Faculty of Health and Medical Research and established the Neuroimmunopharmacology Laboratory. He was awarded an Australian Research Council Australian Research Fellowship in 2011, and an ARC Future Fellowship in 2018. In 2014 he became the Director of the ARC Centre of Excellence for Nanoscale BioPhotonics and remains in this position today.
The Neuroimmunopharmacology Laboratory he leads is a world-leading research team, whose main focus is to develop innovative technologies that allow for the early diagnosis and treatment of neurological diseases. Their innovation centre focuses on translational science, developing biomarkers and wearables for real-time monitoring and precision medicine in humans and animals.
Publications
Hutchinson has published over 240 papers [6] including refereed journal articles and conference papers. These have led to over 13000 citations in journals and refereed conference proceedings [7].
Research
Hutchinson's research program focuses on the neuroimmune contributions to chronic pain, stress, and depression, with the aim of developing biomarker tools and novel neuroimmune targeted therapies. He has made significant contributions to the field, particularly in the areas of opioids and central immune signaling, TLR4-dependent neuropathic pain, and objective biomarkers of exaggerated pain.
Hutchinson was the first to demonstrate that opioid-induced immune signaling within the brain and spinal cord modifies the analgesic effects of opioids and contributes to atypical pain-producing actions, tolerance, respiratory depression, and withdrawal. He also discovered Toll-Like Receptor 4 (TLR4) as the non-opioid receptor through which this immune signaling occurs, paving the way for the development of novel neuroimmune targeted therapies.
Furthermore, Hutchinson's work on TLR4-dependent neuropathic pain revealed that pharmacological TLR4 blockade could reverse pain behaviors and that female neurosteroids have TLR4 activity, leading to enhanced TLR4 proinflammatory signaling and heightened pain responses in females. He has also created the first clinical model of neuroimmune pain in healthy individuals, allowing for the development of objective biomarkers of persistent pain.
Funding and awards
Hutchinson's research program has been consistently funded, with over $71.3 million in career funding, including over $54 million from the National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC). He has received numerous awards, including the Inaugural Coppoc ONE Health Lecture at the College of Veterinary Medicine [8], Kansas State University, the 2019 Vice-Chancellor’s Award for Outstanding Achievement, and the 2015 James McWha Award of Excellence [9]
Personal life
Hutchinson was raised in the Sydney suburb of North Ryde and moved to Adelaide in the mid 1980's. He married Amanda in 2000. Amanda is an Associate Professor in Psychology at the University of South Australia. They have two daughters.
- ^ STA-admin (2021-11-25). "Science innovator and entrepreneur Mark Hutchinson starts as STA President". Science and Technology Australia. Retrieved 2023-05-02.
- ^ "Appointment of 2021 ARC Advisory Council". ARC Media. 22 October 2021. Retrieved 2 May 2023.
- ^ "Biotech alliance announced at ADSTAR 2022". Defence Media. 22 July 2022. Retrieved 2 May 2023.
- ^ "lumen -- Scientist rubs shoulders with celebrities". www.adelaide.edu.au. Retrieved 2023-05-02.
- ^ "Strong drugs without the addiction". www.adelaide.edu.au. Retrieved 2023-05-02.
- ^ "ORCID". orcid.org. Retrieved 2023-05-02.
- ^ "Prof Mark R Hutchinson". scholar.google.com.au. Retrieved 2023-05-02.
- ^ "New Coppoc ONE Health Lecture to feature renowned international neuroscientist". www.k-state.edu. Retrieved 2023-05-02.
- ^ "lumen -- James McWha Award". www.adelaide.edu.au. Retrieved 2023-05-02.
| Submission declined on 2 May 2023 by
DoubleGrazing (
talk). This submission is not adequately supported by
reliable sources. Reliable sources are required so that information can be
verified. If you need help with referencing, please see
Referencing for beginners and
Citing sources. The content of this submission includes material that does not meet Wikipedia's
minimum standard for inline citations. Please
cite your sources using
footnotes. For instructions on how to do this, please see
Referencing for beginners. Thank you.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
| |
- Comment: Insufficiently referenced. Please note that per
WP:BLP, in articles on living people every material statement, anything potentially contentious, and all private personal and family details must be clearly supported by inline citations to reliable published sources.
DoubleGrazing (
talk) 08:56, 2 May 2023 (UTC)
Mark Hutchinson | |
|---|---|
|
File:Mark Hutchinson - Australian Research Council Centre of Excellence for Nanoscale BioPhotonics - University of Adelaide Mark Hutchinson in 2020 | |
| Born | Mark Rowland Hutchinson 1978 (age 45–46) |
| Nationality | Australian |
| Alma mater | University of Adelaide (PhD) |
| Scientific career | |
| Fields | |
| Institutions | |
| Thesis | Opioids and immune function: The role of non-classical opioid receptors and the association with pain perception (2004) |
| Website | https://researchers.adelaide.edu.au/profile/mark.hutchinson |
Mark Rowland Hutchinson (born 1978) is an Australian scientist and academic who is recognized for his significant contributions to the field of neuroimmunology, particularly in the areas of pain, stress, and drug dependence. He is currently a Professor in the School of Biomedicine at the University of Adelaide and Director of the ARC Centre of Excellence for Nanoscale BioPhotonics. He leads the Neuroimmunopharmacology laboratory and is the Lead of the Human Integrated Sensory System Program for the Defence Science Technology Group. He is currently the President. [1] of Science and Technology Australia, member of the Australian Research Council CEO Advisory committee [2], founding member of the Defence Science Technology Group Advisory Council responsible for overseeing the CBRN STaR Shot, co-chair of the SABRE (Safeguarding Australia through Biotechnology Response and Engagement) Alliance [3], founding executive member of The Animal Welfare Collaborative (TAWC), chair of the Australian Pain Solutions Alliance steering committee, and chair of the Davies Livestock Research Centre Advisory Board.
Education
Hutchinson received a Bachelor of Science degree with majors in Immunology, Microbiology, and Pharmacology from the University of Adelaide. This was followed by a first class Honours in Pharmacology. He then pursued a Doctor of Philosophy degree in Medicine with a focus on Pharmacology from the same university in 2004. His is passionate about life long learning and has recently received training in not-for-profits board of directors from the Australian Institute for Company Directors.
Career and research
Hutchinson's research career began in 2004 as a postdoctoral researcher at the University of Colorado Boulder with Distinguished Professors Linda Watkins and Steven Maier. Here we was supported by an American Australian Association Merck Company Foundation Fellowship [4] and an NHMRC CJ Martin Fellowship [5]. In 2009 he returned to the University of Adelaide in the Faculty of Health and Medical Research and established the Neuroimmunopharmacology Laboratory. He was awarded an Australian Research Council Australian Research Fellowship in 2011, and an ARC Future Fellowship in 2018. In 2014 he became the Director of the ARC Centre of Excellence for Nanoscale BioPhotonics and remains in this position today.
The Neuroimmunopharmacology Laboratory he leads is a world-leading research team, whose main focus is to develop innovative technologies that allow for the early diagnosis and treatment of neurological diseases. Their innovation centre focuses on translational science, developing biomarkers and wearables for real-time monitoring and precision medicine in humans and animals.
Publications
Hutchinson has published over 240 papers [6] including refereed journal articles and conference papers. These have led to over 13000 citations in journals and refereed conference proceedings [7].
Research
Hutchinson's research program focuses on the neuroimmune contributions to chronic pain, stress, and depression, with the aim of developing biomarker tools and novel neuroimmune targeted therapies. He has made significant contributions to the field, particularly in the areas of opioids and central immune signaling, TLR4-dependent neuropathic pain, and objective biomarkers of exaggerated pain.
Hutchinson was the first to demonstrate that opioid-induced immune signaling within the brain and spinal cord modifies the analgesic effects of opioids and contributes to atypical pain-producing actions, tolerance, respiratory depression, and withdrawal. He also discovered Toll-Like Receptor 4 (TLR4) as the non-opioid receptor through which this immune signaling occurs, paving the way for the development of novel neuroimmune targeted therapies.
Furthermore, Hutchinson's work on TLR4-dependent neuropathic pain revealed that pharmacological TLR4 blockade could reverse pain behaviors and that female neurosteroids have TLR4 activity, leading to enhanced TLR4 proinflammatory signaling and heightened pain responses in females. He has also created the first clinical model of neuroimmune pain in healthy individuals, allowing for the development of objective biomarkers of persistent pain.
Funding and awards
Hutchinson's research program has been consistently funded, with over $71.3 million in career funding, including over $54 million from the National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC). He has received numerous awards, including the Inaugural Coppoc ONE Health Lecture at the College of Veterinary Medicine [8], Kansas State University, the 2019 Vice-Chancellor’s Award for Outstanding Achievement, and the 2015 James McWha Award of Excellence [9]
Personal life
Hutchinson was raised in the Sydney suburb of North Ryde and moved to Adelaide in the mid 1980's. He married Amanda in 2000. Amanda is an Associate Professor in Psychology at the University of South Australia. They have two daughters.
- ^ STA-admin (2021-11-25). "Science innovator and entrepreneur Mark Hutchinson starts as STA President". Science and Technology Australia. Retrieved 2023-05-02.
- ^ "Appointment of 2021 ARC Advisory Council". ARC Media. 22 October 2021. Retrieved 2 May 2023.
- ^ "Biotech alliance announced at ADSTAR 2022". Defence Media. 22 July 2022. Retrieved 2 May 2023.
- ^ "lumen -- Scientist rubs shoulders with celebrities". www.adelaide.edu.au. Retrieved 2023-05-02.
- ^ "Strong drugs without the addiction". www.adelaide.edu.au. Retrieved 2023-05-02.
- ^ "ORCID". orcid.org. Retrieved 2023-05-02.
- ^ "Prof Mark R Hutchinson". scholar.google.com.au. Retrieved 2023-05-02.
- ^ "New Coppoc ONE Health Lecture to feature renowned international neuroscientist". www.k-state.edu. Retrieved 2023-05-02.
- ^ "lumen -- James McWha Award". www.adelaide.edu.au. Retrieved 2023-05-02.